SCHEMBL6005714

SCHEMBL6005714

CC(C(=O)N[C@H]1N=C(c2ccccc2)c2ccccc2N(C)C1=O)/C(=N\O)c1ccc(F)c(F)c1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CCKBR P32239 11/20 0.65
PSEN1 P49768 3/20 0.63
PSEN2 P49810 3/20 0.63
APH1B Q8WW43 3/20 0.63
NCSTN Q92542 3/20 0.63
APH1A Q96BI3 3/20 0.63
PSENEN Q9NZ42 3/20 0.63
CCKAR P32238 6/20 0.58
NOTCH1 P46531 1/20 0.58
NOTCH3 Q9UM47 1/20 0.58
GSAP A4D1B5 1/20 0.57
GABRP O00591 1/20 0.56
GABRD O14764 1/20 0.56
GABRA1 P14867 1/20 0.56
GABRB1 P18505 1/20 0.56
GABRG2 P18507 1/20 0.56
GABRB3 P28472 1/20 0.56
GABRA5 P31644 1/20 0.56
GABRA3 P34903 1/20 0.56
GABRA2 P47869 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6005717 1.00 CCKBR (0.65) CCKBRPSEN1PSEN2APH1BNCSTN
SCHEMBL6005194 0.90 CCKBR (0.69) CCKBRPSEN1PSEN2APH1BNCSTN
SCHEMBL6005697 0.88 CCKBR (0.65) CCKBRCCKARGABRPGABRDGABRA1
SCHEMBL6005695 0.88 CCKBR (0.65) CCKBRCCKARGABRPGABRDGABRA1
SCHEMBL6003719 0.81 PSEN1 (0.85) CCKBRPSEN1PSEN2APH1BNCSTN
SCHEMBL6003673 0.81 CCKBR (0.67) CCKBRPSEN1PSEN2APH1BNCSTN
SCHEMBL9868116 0.79 CCKBR (1.00) CCKBRCCKARKCNH2
SCHEMBL9868120 0.79 CCKBR (1.00) CCKBRCCKARKCNH2
SCHEMBL6005055 0.79 NOTCH1 (0.68) CCKBRPSEN1PSEN2APH1BNCSTN
SCHEMBL4990878 0.78 PSEN1 (0.82) CCKBRPSEN1PSEN2APH1BNCSTN

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7105509-B2 Benzodiazepine derivatives as APP modulators MERCK SHARP & DOHME LIMITED (GB) 2006-09-12 US disclosed
US-20040082572-A1 Benzodiazepine derivatives as app modulators MERCK SHARPE & DOHME LIMITED (GB) 2004-04-29 US disclosed
EP-1294702-A1 BENZODIAZEPINE DERIVATIVES AS APP MODULATORS MERCK SHARP & DOHME LTD. (GB) 2003-03-26 EP disclosed
WO-2001090084-A1 BENZODIAZEPINE DERIVATIVES AS APP MODULATORS MERCK SHARP & DOHME LIMITED (GB) 2001-11-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040082572-A1 Benzodiazepine derivatives as app modulators BACE1, PSEN1, APP CCKBR 642/4885PSEN1 2/4885PSEN2 9/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.